Alzheon

Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer and Strengthens Commercial Organization with New Executive Appointments to Lead Planned U.S. Commercial Launch of Oral ALZ-801/Valiltramiprosate in 2025

Retrieved on: 
Tuesday, December 5, 2023

“Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.

Key Points: 
  • “Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.
  • He has more than 20 years of commercial launch, sales, market access, and leadership experience in the biopharmaceutical industry.
  • Previously, Mr. Greene held commercial and executive roles at Janssen, Otsuka, and Biogen, with over a dozen launches in CNS disorders and Alzheimer’s.
  • Having these strong leaders further enhances our ability to establish critical partnerships and patient advocacy programs to support a successful commercial launch in 2025.”

Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium

Retrieved on: 
Tuesday, October 31, 2023

Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.
  • This panel will be moderated by Truist analyst, Robyn Karnauskas, PhD.
  • “Alzheon’s simple oral tablet has the potential to address a large unmet need from both an access and treatment perspective.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure neurotoxic amyloid oligomers in CSF.

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer’s Disease Conference

Retrieved on: 
Tuesday, October 17, 2023

We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral anti-amyloid disease modifying therapy for Alzheimer’s disease,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.

Key Points: 
  • We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral anti-amyloid disease modifying therapy for Alzheimer’s disease,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • “Our efficacy data combined with a favorable safety profile with no events of vasogenic edema underscore the differentiated clinical profile of ALZ-801 tablet.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure the neurotoxic amyloid oligomers in CSF.

Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer’s Disease Day, and BIO Investor Forum

Retrieved on: 
Tuesday, September 26, 2023

Event: BIO Investor Forum , independent biotech industry event dedicated to showcasing leading drug development programs for partnering and venture investments.

Key Points: 
  • Event: BIO Investor Forum , independent biotech industry event dedicated to showcasing leading drug development programs for partnering and venture investments.
  • The treatment landscape for Alzheimer’s disease is beginning to take shape and Alzheon’s simplified approach has an opportunity to transform the standard of care and enhance access for patients with Alzheimer’s disease.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal 78-week APOLLOE4 Phase 3 trial , which is now fully enrolled and topline data is expected in the third quarter of 2024.

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

Retrieved on: 
Wednesday, September 13, 2023

“We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral disease modifying therapy for Alzheimer’s disease.

Key Points: 
  • “We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral disease modifying therapy for Alzheimer’s disease.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • In November 2022, Alzheon reported positive study results from a pre-specified analysis following 52 weeks of treatment with ALZ-801.
  • An ongoing long-term extension of the trial evaluates ALZ-801 for an additional 52 weeks of treatment for a total of 156 weeks.

INDRC Appoints Lenka Uldrijanová as Executive Director and Announces Two Peer-Reviewed Scientific Publications

Retrieved on: 
Tuesday, September 5, 2023

Prior to joining INDRC, she led the Czech non-profit organization Liga vozíčkářů, which comprises nearly 100 employees dedicated to helping people with disabilities.

Key Points: 
  • Prior to joining INDRC, she led the Czech non-profit organization Liga vozíčkářů, which comprises nearly 100 employees dedicated to helping people with disabilities.
  • She created effective strategies to maximize donations, identified and explored donor pools with a focus on creating long-term collaborations, and built alliances with other nonprofits.
  • Ms. Uldrijanová is a member of the Regional Chamber of Commerce in Brno, a leading business association in the Czech Republic.
  • Ms. Uldrijanová graduated in 1998 with a master’s degree in history from the Faculty of Sciences of Masaryk University in Brno.

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam

Retrieved on: 
Tuesday, July 11, 2023

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in the third quarter of 2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

Retrieved on: 
Tuesday, April 18, 2023

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in mid-2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden

Retrieved on: 
Wednesday, March 22, 2023

In mechanism of action studies, ALZ-801 fully inhibited the formation of amyloid oligomers at the Phase 3 clinical dose.

Key Points: 
  • In mechanism of action studies, ALZ-801 fully inhibited the formation of amyloid oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial and has the highest likelihood of demonstrating successful efficacy outcomes.
  • “Preventing oligomer formation with an oral tablet is a simplified approach to disease modification in Alzheimer’s.
  • Mikuláš Vlk of IOCB will present the poster, with Dr. Hey and other Alzheon scientists among contributing authors.

Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease

Retrieved on: 
Tuesday, December 6, 2022

In mechanism of action studies, ALZ-801 fully inhibited the formation of amyloid oligomers at the Phase 3 clinical dose.

Key Points: 
  • In mechanism of action studies, ALZ-801 fully inhibited the formation of amyloid oligomers at the Phase 3 clinical dose.
  • The recent announcement of industry-leading disease modifying effects from our Phase 2 biomarker trial of oral ALZ-801 in Alzheimers patients provided further validation of Alzheons approach in blocking formation of amyloid oligomers and attracted enthusiastic investor support.
  • Our lead Alzheimers clinical candidate, ALZ-801 (valiltramiprosate) , is an oral agent in Phase 3 development as a potentially disease modifying treatment for AD.
  • ALZ-801is an oral small molecule that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain.